Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Source: SeekingAlpha
2026-04-06 22:05:16 ET
Shares of Iovance Biotherapeutics ( IOVA ) have lost nearly two-thirds of their value since Amtagvi was approved in February 2024. On the other hand, shares were up by as much as 80% YTD mid-March due to increasing enthusiasm for Amtagvi's commercial prospects in melanoma along with accelerating clinical momentum plus improving margins (transitioning from science project to viable business)....
Read the full article on Seeking Alpha
For further details see:
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
